Stephen Michael Kelsey - 16 Jun 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: President, Research and Development
Issuer ticker: RVMD
Reported as of: 16 Jun 2026
Net transaction value: -$651,798
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:10:00 UTC
Prior SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey

Key filing fact

Stephen Michael Kelsey filed Form 4 for Revolution Medicines, Inc. (RVMD) on 18 Jun 2026.

Key facts

This page summarizes Stephen Michael Kelsey's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2026, 16:10.

Change

Previous filing in this sequence was filed on 19 Mar 2026.
Current net transaction value: -$651,798.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001462808 Primary reporting owner

Kelsey Stephen Michael

Relationship: President, Research and Development
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
Signature date: 18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $651,798
Shares: -4,175
Change %: -1.4%
Price: $156.12
Shares after: 291,876
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F3

Includes 76,251 RSUs.

Footnote F4

Includes 653 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

SEC remarks

President, Research and Development